Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

306.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 306.04
Bid (Size) 213.82 (1)
Ask (Size) 319.94 (2)
Prev. Close 306.04
Today's Range 306.04 - 306.04
52wk Range 208.62 - 306.78
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily

Performance

YTD
+34.61%
+34.61%
1 Month
+11.42%
+11.42%
3 Month
+29.28%
+29.28%
6 Month
+35.71%
+35.71%
1 Year
+36.99%
+36.99%

More News

Read More
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Expert Ratings For United Therapeutics
Via Benzinga
The Latest Analyst Ratings For United Therapeutics
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals.
Via Chartmill
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Via InvestorPlace
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
Via Investor's Business Daily
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
3 Biotech Stocks to Double Your Money in the Next 24 Months
Via InvestorPlace
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
Via Benzinga
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.